rs142552223

GWAS Catalog Trait Associations (6)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

TNF-related apoptosis-inducing ligand measurement

Allele A
OR 0.44
p 4.0e-56
N 21,758
Large GWAS
European

tumor necrosis factor ligand superfamily member 11 measurement

Allele G
OR 0.81
p 2.0e-25
N 3,394
Large GWAS
European

tyrosine measurement

Zoodsma M et al. A genetic map of human metabolism across the allele frequency spectrum. Nature Genetics 57(10):2445-2455 (2025)
Allele A
OR 0.04
p 5.0e-15
N 450,015
Large GWAS
multi-ancestry

hematocrit

Allele A
OR 0.04
p 5.0e-13
N 928,679
Large GWAS
multi-ancestry

gout

Major TJ et al. A genome-wide association analysis reveals new pathogenic pathways in gout. Nature Genetics 56(11):2392-2406 (2024)
Allele A
OR 1.09
p 3.0e-11
N 2,206,883
Large GWAS
European

monocyte percentage of leukocytes

Allele A
OR 0.05
p 5.0e-9
N 170,494
Large GWAS
European

Research that mentions this SNP (1)

Genetic variants in five novel loci including CFB and CD40 predispose to chronic hepatitis B
AssociationN=6,033Jiang DK et al.(2015)· Hepatology

A genome-wide association study of 83 plasma proteins relevant to cardiovascular disease in 3,394 European subjects identified 79 genome-wide significant loci (p<5e-8), with 55 replicating in independent cohorts (n=2,639). Using eQTL analysis and network methods, the authors proposed plausible causal mechanisms for 25 trans-acting loci including post-translational regulation of KITLG by MMP9 and several receptor-ligand pairs. Multiple loci showed evidence of causal association with coronary artery disease risk.

Traits studied:AtherosclerosisCoronary artery diseasePlaque rupturePlasma protein levels (83 cardiovascular disease-related proteins)Thrombosis

This variant is in our database but has no known associations or PRS memberships yet.

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…